A similar argument can be made for other cancer prevention agents with particular molecular targets, such as the epidermal growth factor receptor (EGFR) inhibitor erlotinib for the prevention of head and neck cancer.76 Erlotinib, in combination with celecoxib, was used in a Phase Ib/pharmacokinetic study of head and neck cancer prevention among individuals with oral leukoplakia, dysplasia, and carcinoma in situ. The gene discussed is EGFR; the disease is in situ carcinoma.